Free Trial

Kronos Bio Q4 2022 Earnings Report

Kronos Bio logo
$0.96 0.00 (0.00%)
(As of 12/17/2024 ET)

Kronos Bio EPS Results

Actual EPS
-$0.56
Consensus EPS
-$0.55
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Kronos Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Kronos Bio Announcement Details

Quarter
Q4 2022
Time
N/A

Conference Call Resources

DeFi Coin on Verge of Breakout! (Ad)

[FREE BOOK] Can You Make a Fortune in Crypto with $50? Get started now before the market takes off!

Click here to request your free copy NOW!

Kronos Bio Earnings Headlines

Kronos Bio Inc Ordinary Shares
DeFi Coin on Verge of Breakout!
[FREE BOOK] Can You Make a Fortune in Crypto with $50? Get started now before the market takes off!
Kronos Bio announces workforce reduction of 83% by year-end
Kronos Bio to lay off 83% of staff as CEO steps down
See More Kronos Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kronos Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kronos Bio and other key companies, straight to your email.

About Kronos Bio

Kronos Bio (NASDAQ:KRON), a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.

View Kronos Bio Profile

More Earnings Resources from MarketBeat

Upcoming Earnings